Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients

analysis of the Scottish real life experience

Kelly Rust, Pavlina Spiliopoulou, Chee Yuan Tang, Christine Bell, Diane Stirling, Tze Hui Fifi Phang, Rosemarie Davidson, Melanie Mackean, Fiona Nussey, Ros Glasspool, Nick Reed, Azmat Sadozye, Mary Porteous, Trevor McGoldrick, Michelle Ferguson, Zofia Miedzybrodzka, Iain A McNeish, Charlie Gourley

Research output: Contribution to journalArticle

3 Citations (Scopus)
4 Downloads (Pure)

Abstract

OBJECTIVE: To determine the rate of germline BRCA1 and BRCA2 mutations in Scottish ovarian cancer patients before and after a change in testing policy.

DESIGN: Retrospective cohort study.

SETTING: Four cancer/genetics centres in Scotland.

POPULATION: Ovarian cancer patients undergoing germline BRCA1 and BRCA2 (gBRCA1/2) gene sequencing before 2013 ('old criteria'; selection based solely on family history), after 2013 ('new criteria'; sequencing offered to newly presenting non-mucinous ovarian cancer patients) and the 'prevalent population' (who presented before 2013, were not eligible for sequencing under the old criteria but were sequenced under the new criteria).

METHODS: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria.

MAIN OUTCOME MEASURES: Frequency of germline BRCA1, BRCA2, RAD51C and RAD51D mutations.

RESULTS: Of 599 patients sequenced, 205, 236 and 158 were in the 'old criteria', 'new criteria' and 'prevalent' populations respectively. The frequency of gBRCA1/2 mutations was 30.7%, 13.1% and 12.7% respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. 48% (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score <15 and would not have been offered sequencing based on family history criteria. In addition, 20 gBRCA1/2 patients were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients >70 years was 8.2%.

CONCLUSIONS: Sequencing all non-mucinous ovarian cancer patients produces much higher annual gBRCA1/2 mutation detection with the frequency of positive tests still exceeding the 10% threshold upon which many family history based models operate. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)1451-1458
Number of pages8
JournalBJOG-An International Journal of Obstetrics and Gynaecology
Volume125
Issue number11
Early online date10 May 2018
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Life Change Events
Carcinoma
Ovarian Neoplasms
Mutation
BRCA2 Gene
BRCA1 Gene
Scotland
Patient Selection
Population
Cohort Studies
Retrospective Studies
Neoplasms

Keywords

  • Journal Article
  • BRCA1
  • BRCA2
  • RAD51C
  • RAD51D
  • ovarian cancer

Cite this

Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients : analysis of the Scottish real life experience. / Rust, Kelly; Spiliopoulou, Pavlina; Tang, Chee Yuan; Bell, Christine; Stirling, Diane; Phang, Tze Hui Fifi; Davidson, Rosemarie; Mackean, Melanie; Nussey, Fiona; Glasspool, Ros; Reed, Nick; Sadozye, Azmat; Porteous, Mary; McGoldrick, Trevor; Ferguson, Michelle; Miedzybrodzka, Zofia; McNeish, Iain A; Gourley, Charlie.

In: BJOG-An International Journal of Obstetrics and Gynaecology, Vol. 125, No. 11, 10.2018, p. 1451-1458.

Research output: Contribution to journalArticle

Rust, K, Spiliopoulou, P, Tang, CY, Bell, C, Stirling, D, Phang, THF, Davidson, R, Mackean, M, Nussey, F, Glasspool, R, Reed, N, Sadozye, A, Porteous, M, McGoldrick, T, Ferguson, M, Miedzybrodzka, Z, McNeish, IA & Gourley, C 2018, 'Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience', BJOG-An International Journal of Obstetrics and Gynaecology, vol. 125, no. 11, pp. 1451-1458. https://doi.org/10.1111/1471-0528.15171
Rust, Kelly ; Spiliopoulou, Pavlina ; Tang, Chee Yuan ; Bell, Christine ; Stirling, Diane ; Phang, Tze Hui Fifi ; Davidson, Rosemarie ; Mackean, Melanie ; Nussey, Fiona ; Glasspool, Ros ; Reed, Nick ; Sadozye, Azmat ; Porteous, Mary ; McGoldrick, Trevor ; Ferguson, Michelle ; Miedzybrodzka, Zofia ; McNeish, Iain A ; Gourley, Charlie. / Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients : analysis of the Scottish real life experience. In: BJOG-An International Journal of Obstetrics and Gynaecology. 2018 ; Vol. 125, No. 11. pp. 1451-1458.
@article{27ea05634cbb499ab821257421dff89a,
title = "Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience",
abstract = "OBJECTIVE: To determine the rate of germline BRCA1 and BRCA2 mutations in Scottish ovarian cancer patients before and after a change in testing policy.DESIGN: Retrospective cohort study.SETTING: Four cancer/genetics centres in Scotland.POPULATION: Ovarian cancer patients undergoing germline BRCA1 and BRCA2 (gBRCA1/2) gene sequencing before 2013 ('old criteria'; selection based solely on family history), after 2013 ('new criteria'; sequencing offered to newly presenting non-mucinous ovarian cancer patients) and the 'prevalent population' (who presented before 2013, were not eligible for sequencing under the old criteria but were sequenced under the new criteria).METHODS: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria.MAIN OUTCOME MEASURES: Frequency of germline BRCA1, BRCA2, RAD51C and RAD51D mutations.RESULTS: Of 599 patients sequenced, 205, 236 and 158 were in the 'old criteria', 'new criteria' and 'prevalent' populations respectively. The frequency of gBRCA1/2 mutations was 30.7{\%}, 13.1{\%} and 12.7{\%} respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. 48{\%} (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score <15 and would not have been offered sequencing based on family history criteria. In addition, 20 gBRCA1/2 patients were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients >70 years was 8.2{\%}.CONCLUSIONS: Sequencing all non-mucinous ovarian cancer patients produces much higher annual gBRCA1/2 mutation detection with the frequency of positive tests still exceeding the 10{\%} threshold upon which many family history based models operate. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article, BRCA1, BRCA2, RAD51C, RAD51D, ovarian cancer",
author = "Kelly Rust and Pavlina Spiliopoulou and Tang, {Chee Yuan} and Christine Bell and Diane Stirling and Phang, {Tze Hui Fifi} and Rosemarie Davidson and Melanie Mackean and Fiona Nussey and Ros Glasspool and Nick Reed and Azmat Sadozye and Mary Porteous and Trevor McGoldrick and Michelle Ferguson and Zofia Miedzybrodzka and McNeish, {Iain A} and Charlie Gourley",
note = "Funding Information Edinburgh Ovarian Cancer Database Cancer Research UK",
year = "2018",
month = "10",
doi = "10.1111/1471-0528.15171",
language = "English",
volume = "125",
pages = "1451--1458",
journal = "BJOG-An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "11",

}

TY - JOUR

T1 - Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients

T2 - analysis of the Scottish real life experience

AU - Rust, Kelly

AU - Spiliopoulou, Pavlina

AU - Tang, Chee Yuan

AU - Bell, Christine

AU - Stirling, Diane

AU - Phang, Tze Hui Fifi

AU - Davidson, Rosemarie

AU - Mackean, Melanie

AU - Nussey, Fiona

AU - Glasspool, Ros

AU - Reed, Nick

AU - Sadozye, Azmat

AU - Porteous, Mary

AU - McGoldrick, Trevor

AU - Ferguson, Michelle

AU - Miedzybrodzka, Zofia

AU - McNeish, Iain A

AU - Gourley, Charlie

N1 - Funding Information Edinburgh Ovarian Cancer Database Cancer Research UK

PY - 2018/10

Y1 - 2018/10

N2 - OBJECTIVE: To determine the rate of germline BRCA1 and BRCA2 mutations in Scottish ovarian cancer patients before and after a change in testing policy.DESIGN: Retrospective cohort study.SETTING: Four cancer/genetics centres in Scotland.POPULATION: Ovarian cancer patients undergoing germline BRCA1 and BRCA2 (gBRCA1/2) gene sequencing before 2013 ('old criteria'; selection based solely on family history), after 2013 ('new criteria'; sequencing offered to newly presenting non-mucinous ovarian cancer patients) and the 'prevalent population' (who presented before 2013, were not eligible for sequencing under the old criteria but were sequenced under the new criteria).METHODS: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria.MAIN OUTCOME MEASURES: Frequency of germline BRCA1, BRCA2, RAD51C and RAD51D mutations.RESULTS: Of 599 patients sequenced, 205, 236 and 158 were in the 'old criteria', 'new criteria' and 'prevalent' populations respectively. The frequency of gBRCA1/2 mutations was 30.7%, 13.1% and 12.7% respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. 48% (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score <15 and would not have been offered sequencing based on family history criteria. In addition, 20 gBRCA1/2 patients were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients >70 years was 8.2%.CONCLUSIONS: Sequencing all non-mucinous ovarian cancer patients produces much higher annual gBRCA1/2 mutation detection with the frequency of positive tests still exceeding the 10% threshold upon which many family history based models operate. This article is protected by copyright. All rights reserved.

AB - OBJECTIVE: To determine the rate of germline BRCA1 and BRCA2 mutations in Scottish ovarian cancer patients before and after a change in testing policy.DESIGN: Retrospective cohort study.SETTING: Four cancer/genetics centres in Scotland.POPULATION: Ovarian cancer patients undergoing germline BRCA1 and BRCA2 (gBRCA1/2) gene sequencing before 2013 ('old criteria'; selection based solely on family history), after 2013 ('new criteria'; sequencing offered to newly presenting non-mucinous ovarian cancer patients) and the 'prevalent population' (who presented before 2013, were not eligible for sequencing under the old criteria but were sequenced under the new criteria).METHODS: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria.MAIN OUTCOME MEASURES: Frequency of germline BRCA1, BRCA2, RAD51C and RAD51D mutations.RESULTS: Of 599 patients sequenced, 205, 236 and 158 were in the 'old criteria', 'new criteria' and 'prevalent' populations respectively. The frequency of gBRCA1/2 mutations was 30.7%, 13.1% and 12.7% respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. 48% (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score <15 and would not have been offered sequencing based on family history criteria. In addition, 20 gBRCA1/2 patients were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients >70 years was 8.2%.CONCLUSIONS: Sequencing all non-mucinous ovarian cancer patients produces much higher annual gBRCA1/2 mutation detection with the frequency of positive tests still exceeding the 10% threshold upon which many family history based models operate. This article is protected by copyright. All rights reserved.

KW - Journal Article

KW - BRCA1

KW - BRCA2

KW - RAD51C

KW - RAD51D

KW - ovarian cancer

U2 - 10.1111/1471-0528.15171

DO - 10.1111/1471-0528.15171

M3 - Article

VL - 125

SP - 1451

EP - 1458

JO - BJOG-An International Journal of Obstetrics and Gynaecology

JF - BJOG-An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 11

ER -